National Taiwan University Hospital Hsinchu Branch
Hsinchu, Taiwan
Location status: Recruiting
NCT Number: NCT07119580
Background Intact corneal epithelium is important for the defense on the ocular surface, and the function of limbal stem cells is crucial to maintain its integrity. Certain chronic eye diseases, such as glaucoma, require long-term medication use. However, glaucoma patients often exhibit corneal punctate erosions and ocular surface inflammation. In cases where medication has been used for an extended period, patients may even show symptoms similar to limbal stem cell deficiency. Understanding how glaucoma medications affect the function of corneal limbal stem cells is a critical clinical issue.
Objectives To evaluate the effect of glaucoma and anti-glaucoma agents on corneal epithelial and limbal epithelial thickness as a surrogate of limbal stem cell function, and to understand the association between tear fluid proteome and limbal function in glaucoma patients.
Methods We planned to include 90 subjects with glaucoma, and analyze the absolute thickness and variation of corneal epithelium and limbal epithelium. Tear fluid samples will be collected and proteomic analysis will be performed to elucidate the association between protein.
Anticipated Results To elucidate the impact of different types and cumulative doses of glaucoma medications on the thickness of the corneal epithelium and limbal epithelium, and to understand the relationship between limbal function and tear proteomics in glaucoma patients. The expected results may help develop early detection methods for changes in corneal and limbal epithelial function and provide valuable insights for future research on drug design and the protection of limbal stem cells.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Hsinchu, Taiwan
Location status: Recruiting
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
i. Age ≥ 18 years. ii. Healthy Control Group: No diagnosis of glaucoma or ocular hypertension. iii. Glaucoma, Newly Diagnosed Group: Diagnosed with angle-closure glaucoma, open-angle glaucoma, or ocular hypertension; antiglaucoma medication usage for less than 3 months.
iv. Glaucoma, Long-term Medication Group: Diagnosed with angle-closure glaucoma, open-angle glaucoma, or ocular hypertension; continuous use of intraocular pressure-lowering medications for more than 1 year.
v. Glaucoma, Unilateral Group: Diagnosed with unilateral glaucoma or ocular hypertension; only one eye receiving intraocular pressure-lowering treatment.
Exclusion criteria
i. History of severe ocular trauma, chemical burns, corneal ulcers, Stevens-Johnson syndrome with ocular involvement, or ocular graft-versus-host disease.
ii. History of corneal surgery, conjunctival surgery, trabeculectomy, or glaucoma drainage device implantation.
iii. Presence of ocular surface irregularity or limbal dysfunction due to conditions other than glaucoma or dry eye disease.
Time frame: Upon enrollment and at 6 months after enrollment (for newly diagnosed patients)
Limbal epithelial thickness obtained from AS-OCT
Time frame: Upon enrollment and at 6 months after enrollment (for newly diagnosed patients)
Corneal epithelial thickness map obtained from AS-OCT
Time frame: Upon enrollment and at 6 months after enrollment (for newly diagnosed patients)
Proteomic findings of tear samples
Contact information is provided by the study sponsor or research team.
National Taiwan University Hospital
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07036510
Cataract, Eye Diseases
Panama City, Panama
View Trial DetailsNCT07588152
Eye Diseases, Glaucoma
Bloomington, Indiana, United States
View Trial DetailsNCT04024293
Eye Diseases, Glaucoma
Lausanne, Canton of Vaud, Switzerland
View Trial DetailsNCT07217678
Eye Diseases, Glaucoma
Miami, Florida, United States
View Trial Details